You just read:

Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model

News provided by

Kitov Pharmaceuticals Holdings Ltd.

Jul 18, 2017, 08:36 ET